期刊文献+

CD56和CD117不同表达模式在多发性骨髓瘤中的临床特征及预后分析 被引量:1

Clinical and prognostic features in CD56 and CD117 of multiple myeloma patients
原文传递
导出
摘要 目的探讨多发性骨髓瘤(MM)患者CD56和CD117的不同表达模式与疾病临床特征及预后的关系。方法根据流式结果CD56/CD117的表达模式将50例初发MM患者分为双阴组(CD56-CD117-)(n=21)、双阳组(CD56+CD117+)(n=4),CD56阳组(n=20)和CD117阳组(n=5),分析各组患者的一般资料、临床特征、实验室检查结果及预后。结果双阴组骨损害发生率56.8%,均高于双阳组(10.8%)、CD56阳组(32.4%)和CD117阳组(0.0%),差异均有统计学意义(P均<0.0083)。双阴组β2微球蛋白(β2-MG)和肌酐(Crea)水平低于CD117阳组(5.6 mg/L vs.12.2 mg/L;110.0μmol/L vs.469.0μmol/L),CD56阳组Crea水平明显低于CD117阳组(97.5μmol/L vs.469.0μmol/L),差异均有统计学意义(P<0.0083);双阴组免疫固定电泳IgA-L和IgG-K发生率高于CD56阳组,而IgG-L和轻链发生率低于CD56阳组,差异均有统计学意义(P均<0.0083);CD117阳组的IGH重排发生率(80.00%)明显高于双阴组(4.76%),差异均有统计学意义(P<0.0083);四组间国际分期系统(ISS)预后分期差异无统计学意义(P>0.05)。结论CD56和CD117的不同表达模式与MM患者的临床特征密切相关,可提示其预后。 Objective To investigate the relationship between the different expression patterns of CD56/CD117 and the clinical features or prognosis in patients with multiple myeloma(MM).Methods According to the expression pattern of CD56/CD117,50 patients with primary MM were divided into four groups,including 21 cases in the double-negative group(CD56-CD117-),4 cases in the double-positive group(CD56+CD117+),20 cases in the CD56 positive group and 5 cases in the CD117 positive group.The general data,clinical features,laboratory data and prognosis of patients were analyzed.Results The incidence of bone damage in the double-negative group was much higher than that in the double-positive group,CD56 positive group and CD117 positive group(56.8%vs.10.8%,32.4%,0.0%)(P<0.0083).The levels of Beta-2-microglobulin(β2-MG)and creatinine(Crea)in the double-negative group were significantly lower than those in CD117positive group(5.6 mg/L vs.12.2 mg/L;110.0μmol/L vs.469.0μmol/L)(P<0.0083).The Crea level of the CD56 positive group was significantly lower than that of the CD117 positive group(97.5μmol/L vs.469.0μmol/L)(P<0.0083).In the immunofixation electrophoresis,the probability of IgA-L and IgG-K of the double negative group was higher than that of the CD56 positive group,while the probability of IgG-L and the light chain was lower than that of the CD56 positive group(P<0.0083).The incidence of IGH rearrangement in the CD117 positive group(80.00%)was significantly higher than that in the double negative group(4.76%)(P<0.0083).There was no significant difference in the International Staging System(ISS)stage among the four groups(P>0.05).Conclusion The different expression patterns of CD56/CD117 were closely related to the clinical features of MM patients,which might indicate their prognosis.
作者 陈炜烨 韩丽乔 梁恩瑜 涂晓欣 欧阳芬 陈康艺 黄宪章 庄俊华 柯培锋 徐建华 CHEN Wei-ye;HAN Li-qiao;LIANG En-yu;TU Xiao-xin;OU Yang-fen;CHEN Kang-yi;HUANG Xian-zhang;ZHUANG Jun-hua;KE Pei-feng;XU Jian-hua(Department of Laboratory Medicine,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Guangdong Provincial Hospital of Chinese Medicine),Guangzhou,Guangdong 510120;Department of Laboratory Medicine,Nanhai Hospital of Guangdong Provincial People's Hospital,Foshan,Guangdong 528200;Shunde Hospital of Guangzhou University of Chinese Medicine,Foshan,Guangdong 528333,China)
出处 《热带医学杂志》 CAS 2022年第9期1252-1257,共6页 Journal of Tropical Medicine
基金 广东省中医院拔尖人才科研专项资助(BJ2022KY04) 广东省中医院中医药科学技术研究专项(YN2019QL06) 广东省基础与应用基础研究基金(2021A1515220149) 广东省中医药局科研项目(20202070)
关键词 多发性骨髓瘤 CD56 CD117 预后 Multiple myeloma CD56 CD117 Prognosis
作者简介 陈炜烨(1983-),男,硕士,主管技师,从事临检血液的诊断、教学工作;通信作者:柯培锋,E-mail:kevinland020@163.com;通信作者:徐建华,E-mail:jhxu1976@126.com
  • 相关文献

参考文献14

二级参考文献117

  • 1李娟,罗绍凯,张国材,洪文德,童秀珍.CD_(117)在多发性骨髓瘤细胞中的表达及其意义[J].癌症,2004,23(8):951-954. 被引量:7
  • 2王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学(输血及血液学分册),1993,16(1):35-37. 被引量:11
  • 3庄俊玲,汪玄,武永吉.CD138/Syndecan-1在多发性骨髓瘤免疫表型中的意义[J].中国实验血液学杂志,2005,13(6):1023-1027. 被引量:10
  • 4Kara IO, Sahin B, Paydas S, et al. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Saudi Med J, 2004; 25( 11 ) : 1587 - 1592.
  • 5Braylan RC, Orfao A, Borowitz MJ, et al. Optimal number o4 reagents required to evaluate hematolymphoid neoplasia: results of an international consensus meeting. Cytometry, 2001 ;46 ( 1 ) :23 27.
  • 6Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol, 2004, 121 (4): 482-488.
  • 7Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purification of syndecan-1 ^+ malignant plasma cells. J lmmunol Methods, 1997 ;205 ( 1 ) :73 - 79.
  • 8Matsui W, Huff CA, Wang QJ, et al. Characterization of clonogenic multiple myeloma cells. Blood, 2004 ; 103 (6) : 2332 - 2336.
  • 9Aref S, Goda T, El-Sherbiny M. Syndecan-I in multiple myeloma: relationship to conventional prognostic factors. Hematology, 2003 ; 8(4) :221 -228.
  • 10Yang Y, Yaccoby S, Liu W. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002 ;100(2) :610 -617.

共引文献109

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部